RECRUITING

HNC: Human Neural Circuits Electrophysiology During Cognition

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand how ketamine brings about dissociative symptoms.

Official Title

HNC: Human Neural Circuits Electrophysiology During Cognition

Quick Facts

Study Start:2023-10-05

Study Completion:2026-09-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05962424

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patient in clinical neuro inpatient units at Stanford Medical Center * Age \>18 years old * Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)	* Lifetime psychotic disorder * Pregnant or nursing females * Prior adverse ketamine response * Use of ketamine in past 7 days

Inclusion Criteria

Exclusion Criteria

* Patient in clinical neuro inpatient units at Stanford Medical Center
* Age \>18 years old
* Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)

* Lifetime psychotic disorder
* Pregnant or nursing females
* Prior adverse ketamine response
* Use of ketamine in past 7 days

Contacts and Locations

Study Contact

Arjay Cordero

CONTACT

650-580-9000

arjayc@stanford.edu

Principal Investigator

Karl Deisseroth, MD, PhD

PRINCIPAL_INVESTIGATOR

Stanford University

Study Locations (Sites)

Stanford University

Palo Alto, California, 94306

United States

Collaborators and Investigators

Sponsor: Stanford University

Karl Deisseroth, MD, PhD, PRINCIPAL_INVESTIGATOR, Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-05

Study Completion Date2026-09-01

Study Record Updates

Study Start Date2023-10-05

Study Completion Date2026-09-01

Terms related to this study

Additional Relevant MeSH Terms

Psychiatric Disorder